Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

by rvvadmin | Apr 3, 2023 | 2023

Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023 –  Revive Therapeutics Ltd. (“Revive” or the...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

by rvvadmin | Mar 28, 2023 | 2023

First subject enrolled and initial top-line results expected in Q3-2023 TORONTO, March 28, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and...

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

by rvvadmin | Mar 20, 2023 | 2023

TORONTO, March 20, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

by rvvadmin | Mar 8, 2023 | 2023

FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support unblinding of the data to potentially provide evidence of efficacy TORONTO, March 08, 2023 – Revive Therapeutics Ltd. (“Revive” or...

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

by rvvadmin | Feb 6, 2023 | 2023

TORONTO, Feb. 06, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...